meganyl 50 mg/ml oldatos injekció szarvasmarhák, sertések és lovak számára a.u.v.
laboratorios syva s.a. - flunixin - oldatos injekció - flunixin - szarvasmarha, sertés, ló
procactive 300 mg/ml szuszpenziós injekció szarvasmarhák , juhok és sertések számára a.u.v.
laboratorios syva s.a. - benzilpenicillin-prokain-monohidrát - szuszpenziós injekció - procaine penicillin - szarvasmarha, juh, sertés
nasym
laboratorios hipra s.a. - élő, attenuált szarvasmarha légzőszervi rs vírus (brsv), törzs lym-56 - immunológikumok a szarvasmarhafélék, szarvasmarha, Élő vírusos vakcinák, szarvasmarha légzőszervi rs vírus (brsv) - marha - aktív immunizálására szarvasmarha, hogy csökkenti a vírus hajtását, valamint légúti klinikai tünetek okozta szarvasmarha légzőszervi rs vírus fertőzés.
suiseng coli / c szuszpenziós injekció sertéseknek
laboratorios hipra s.a. - clostridium novyi, escherichia coli, clostridium perfringens - szuszpenziós injekció - escherichia vaccine + clostridium vaccine - sertés
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sertés - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
febuxostat bausch 80 mg filmtabletta
laboratorios liconsa sa - febuxostat -
febuxostat bausch 120 mg filmtabletta
laboratorios liconsa sa - febuxostat -
nátrium-klorid grifols 0,9% oldatos infúzió
laboratorios grifols, s.a. - nátrium-klorid -
suiseng diff/a
laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - sertés - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.
adresalf 1 mg/ml koncentrátum oldatos injekcióhoz
s.a.l.f. s.p.a. laboratorio farmacologico - adrenalin (adrenalin) -